NEXUS Epigenomics AB is a Swedish biotech company developing scalable, enzyme-based technologies for genome-wide epigenomic profiling. Its lead platform, MeTLAND® captures high-quality methylated DNA from low-input and clinically relevant samples. The company is a spinout from research conducted at the Karolinska Institute and Stockholm University, and is supported with funding from the European Research Council, KI Innovations, SU Innovations, and Sweden’s largest bank, SEB.